Xenetic Biosciences, Inc. (XBIO) - חוב לטווח ארוך להון

Xenetic Biosciences (XBIO) automates the creation of DNase-based oncology drugs via robotic screening, minimizing manual labor for biologists. The company is also developing a platform for vaccine optimization and immune management. This price chart reflects the dynamics of debt obligations, which currently stand at 0.00. High market confidence is driven by the success of the XCART system for personalized cell therapy and strict adherence to scientific standards.

Xenetic Biosciences (XBIO) occupies a narrow niche in the development of enzyme-based cancer treatments. By analyzing the share of long-term loans within the capital structure, an investor assesses the ratio of liabilities with a maturity of over one year to equity. This metric determines the degree of financial autonomy and reliance on borrowed funds. For a biotech firm dependent on external investment, a low debt level reduces bankruptcy risk in the event of clinical trial delays. The market views a minimal debt load as a guarantee of the company's stability.